AAIC 2026: Satellite Symposia and Sponsors

AAIC 2026 Satellite Symposia and Sponsors

The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles served as a critical venue for industry engagement in Alzheimer's disease research. Satellite symposia, organized by pharmaceutical companies, biotechnology firms, and research organizations, provided in-depth coverage of pipeline programs, clinical trial results, and therapeutic strategies that complement the scientific sessions of the main conference[@aaic2026].

Overview

AAIC 2026 Satellite Symposia and Sponsors

The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles served as a critical venue for industry engagement in Alzheimer's disease research. Satellite symposia, organized by pharmaceutical companies, biotechnology firms, and research organizations, provided in-depth coverage of pipeline programs, clinical trial results, and therapeutic strategies that complement the scientific sessions of the main conference[@aaic2026].

Overview

The satellite symposia program at AAIC 2026 represents a vital component of the conference, providing companies with opportunities to present detailed data, engage with key opinion leaders, and discuss their therapeutic pipelines with the research community. These sessions complement the abstract-driven presentations of the main sessions by offering more comprehensive updates on specific therapeutic approaches and corporate research strategies.

The 2026 satellite symposia reflected the evolving Alzheimer's disease therapeutic landscape, which has been transformed by the approval of disease-modifying anti-amyloid antibodies and the continued advancement of tau-targeted, neuroprotective, and precision medicine approaches. The field has moved from a period of repeated clinical trial failures to one of unprecedented optimism, with multiple agents demonstrating amyloid clearance and potential clinical benefit["@scheltens2023"][@cummings2024].

Platinum Sponsors

Major Pharmaceutical Partners

Biogen
Biogen's Alzheimer's franchise has evolved significantly following the conditional approval and subsequent withdrawal of aducanumab (Aduhelm). The company continues to pursue next-generation approaches targeting multiple mechanisms:

• Anti-amyloid portfolio: Development of next-generation monoclonal antibodies with improved efficacy and safety profiles
• BACE inhibitors: Early intervention strategies targeting beta-secretase
• Tau programs: Partnerships for anti-tau therapeutic development
• Neuroprotection: Small molecule approaches for synapse preservation

Eisai
Eisai, in partnership with Biogen, brought lecanemab (Leqembi) to market as the first fully approved anti-amyloid antibody demonstrating both amyloid clearance and clinical benefit. The company's satellite symposium provided:

• Real-world effectiveness data: Post-approval clinical experience with lecanemab
• Clarity ARIA management: Optimized protocols for amyloid-related imaging abnormalities
• Biomarker correlatives: CSF and blood-based marker changes accompanying treatment
• Combination strategies: Plans for combination therapy approaches

Eli Lilly
Eli Lilly's donanemab (Kisunla) achieved FDA approval as the second anti-amyloid antibody demonstrating disease modification in early Alzheimer's disease. The company's satellite symposium featured:

• TRAILBLAZER-ALZ 2 results: Full Phase 3 data in low/medium and high tau populations
• Remternetug: Next-generation anti-amyloid antibody in Phase 3
• Tau imaging programs: Development of tau PET endpoints for clinical trials
• Precision medicine approach: Targeting patients based on tau pathology burden

Roche/Genentech
Roche's comprehensive Alzheimer's program spans multiple mechanisms:

• Gantenerumab (RG1450): Anti-amyloid antibody completing development program
• Tau programs: Anti-tau antibodies in clinical development
• TREM2 modulation: Agonist antibodies targeting microglial activation
• Diagnostic partnerships: Collaboration on biomarker development

Johnson & Johnson
Johnson & Johnson's neuroscience pipeline includes:

• Amyloid-targeting programs: Early-stage anti-amyloid development
• Tau programs: Anti-tau antibody development
• Genetic subtype approaches: Precision medicine for LRRK2 and other genetic variants
• Diagnostic development: Biomarker strategies for patient selection

Biotechnology Partners

AC Immune
AC Immune has established itself as a leader in immunotherapy approaches for neurodegenerative diseases:

• ACI-35: Phospho-tau active vaccination program
• Anti-tau antibodies: Monoclonal antibodies targeting pathological tau
• Alpha-synuclein programs: Immunotherapy for Lewy body diseases
• Small molecule inhibitors: Aggregation inhibitors for multiple proteins

Prothelia
Prothelia focuses on prion protein and protein misfolding diseases:

• Anti-PrP antibodies: Targeting prion protein in Alzheimer's and prion disease
• Oligomer-targeted approaches: Focusing on toxic soluble oligomers
• Combination strategies: Dual-targeting approaches

• CT1812 (Sореnemetostat): Sigma-2 receptor modulator in Phase 2
• Synaptic protection: Mechanisms targeting synapse degeneration
• Alzheimer's and Parkinson's programs: Pipeline across neurodegenerative diseases

Satellite Symposia Sessions

Morning Sessions

| Company | Topic | Highlights |
|---------|-------|------------|
| Eisai | Lecanemab Updates | Real-world efficacy data, ARIA management protocols, biomarker correlatives |
| Lilly | Anti-Tau Pipeline | Donanemab full results, remternetug Phase 3, tau PET endpoints |
| Biogen | Next-Gen Approaches | Novel mechanisms beyond amyloid, early intervention strategies |
| Roche | TREM2 Modulation | Agonist antibody data, microglial activation targeting |
| AC Immune | Vaccine Platforms | ACI-35 phospho-tau vaccine results, immunotherapy pipeline |

Afternoon Sessions

| Company | Topic | Highlights |
|---------|-------|------------|
| J&J | Genetic Subtypes | LRRK2 targeting, precision medicine approaches |
| Prothelia | Prion Protein | Oligomer-targeted therapies |
| Cognition | Sigma-2 Modulators | CT1812 Phase 2 results, synaptic protection |
| Diagnostics | Biomarker Platforms | Blood-based biomarker development, point-of-care testing |

Session Highlights

Anti-Amyloid Therapy Updates

The satellite symposia provided detailed updates on anti-amyloid therapeutic development:

Amyloid-Related Imaging Abnormalities (ARIA) Management

• Updated consensus guidelines for ARIA detection and management
• Monitoring protocols using MRI and clinical assessment
• Risk factors including APOE4 genotype, anticoagulation use
• Strategies for managing ARIA while maintaining therapeutic benefit[barakos2024]

• Amyloid PET standardized uptake value ratio (SUVr) changes
• CSF amyloid and tau biomarker shifts
• Blood-based biomarker changes (p-tau181, p-tau217)
• Correlation with clinical outcomes[hansson2024]

• Dosing regimens for optimal amyloid clearance
• Treatment duration and potential for discontinuation after clearance
• Combination therapy approaches with other mechanisms

Tau-Targeting Therapies

Tau remains the second major therapeutic target in Alzheimer's disease:

Anti-Tau Antibodies

• Multiple antibodies in clinical development
• Target different epitopes and tau species
• PET imaging for target engagement and treatment response

• Small molecules targeting tau aggregation
• Mechanisms of action and clinical development status
• Combination with anti-amyloid approaches[tahami-monfared2024]

• Active immunization against pathological tau
• ACI-35 and similar programs
• Challenges with immune response and antibody generation

Neuroinflammation and Microglial Activation

The role of neuroinflammation in Alzheimer's pathogenesis has gained significant attention:

TREM2 Targeting

• TREM2 agonist antibodies
• TREM2 genetic variants and their effects on disease risk
• Microglial modulation strategies[wang2024]

• Complement inhibitors for neuroinflammation
• C1q targeting approaches
• Synaptic protection mechanisms

• Phenotypic changes in Alzheimer's disease
• Therapeutic targeting of specific microglial states
• Biomarkers of neuroinflammation[bassetti2024]

Industry Sponsored Research

Investigator-Initiated Studies

Industry partnerships with academic researchers support:

• Biomarker validation studies: Independent validation of biomarker assays
• Real-world evidence collection: Clinical outcomes in diverse populations
• Subgroup analyses: Understanding treatment effects across patient populations
• Long-term follow-up: Extended observation of treated patients

Data Sharing Initiatives

Collaborative approaches to advancing research:

• Public-private partnerships: Coalition for Alzheimer's drug discovery
• Cross-company data harmonization: Standardized data formats and endpoints
• Open science frameworks: Pre-competitive collaboration on basic mechanisms
• Trial data sharing: Access to clinical trial datasets for secondary analyses

Research Grants and Fellowships

Alzheimer's Association Grants

The Alzheimer's Association supports research through:

• AAIC Awards: Young investigator awards presented at the conference
• Part the Cloud: Funding for translational research
• Strategic Fund: Priority research areas including biomarkers and precision medicine
• International Collaborations: Global research partnerships

Industry Fellowships

Pharmaceutical and biotechnology companies provide:

• Postdoctoral fellowships: Training the next generation of researchers
• Clinical research training: Development of clinical trial expertise
• Technology development grants: Supporting innovation in diagnostics and digital health

Exhibit Hall Highlights

Booth Presentations

Demo Theaters

• Product information sessions
• Device demonstrations
• Technology tutorials

• Company-sponsored scientific presentations
• Late-breaking research
• Pipeline updates

• Partnering opportunities
• Academic collaborations
• Clinical trial discussions

Technology Showcase

Diagnostic Platforms

• Blood-based biomarker testing systems
• Point-of-care testing devices
• CSF assay automation

• Wearable devices for cognitive monitoring
• Remote patient monitoring platforms
• Telehealth solutions

• Data analysis platforms
• Clinical trial optimization
• Patient stratification algorithms

Therapeutic Pipeline Overview

The satellite symposia reflected the robust Alzheimer's disease therapeutic pipeline[cummings2024]:

Phase 3 Programs

• Multiple anti-amyloid antibodies in late-stage development
• Tau-targeted agents advancing
• Neuroprotective and disease-modifying approaches

Phase 2 Programs

• Novel mechanisms including TREM2 modulators
• Anti-inflammatory approaches
• Metabolic and vascular targeting

Phase 1 Programs

• Gene therapy approaches
• Cell-based therapies
• Novel small molecule mechanisms

Key Takeaways

Related Pages

• [AAIC 2026 Conference](/events/aaic-2026)](/events)
• [AAIC 2026 Company Presentations](/events/aaic-2026-company-presentations)](/events)
• [AAIC 2026 Emerging Therapeutic Targets](/events/aaic-2026-emerging-therapeutic-targets)](/events)
• [AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)](/clinical-trials)
• [AAIC 2026 Posters and Abstracts](/events/aaic-2026-posters-abstracts)](/events)
• [Lecanemab](/therapeutics/lecanemab)](/therapeutics)
• [Donanemab](/therapeutics/donanemab)](/therapeutics)
• [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)](/therapeutics)
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)](/therapeutics)
• [TREM2](/proteins/trem2)

References